B+
Bull case
25%
Probability
Target price
$0.28
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
NXGL
NexGelCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.19
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+68.3
Score
AI commentary
Cautious monitoring view despite a positive deterministic directional prior. The packet provides no verified recent news tone, post-release price reaction, analyst revisions, options skew, short interest, employee score, or sufficiently covered social reading. Zero-valued sentiment fields denote unavailable data, not neutral measurements.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventBioNX Surgical backlog conversionHigh impact
NEXGEL reported approximately $795,000 of BioNX Surgical backlog, but said supply constraints and a slower-than-anticipated surgical rollout limited product availability. Conversion depends on manufacturing-transfer and fulfillment execution. [#SEC-8K-2026-08-17]
2026-12-31catalystPotential reverse split and share authorizationHigh impact
Shareholders approved board authority to increase authorized common shares from 25 million to as many as 150 million and to effect a discretionary 1-for-2 to 1-for-20 reverse split. Approval does not establish that either action has been implemented. Dilution and trading risks remain material. [#SEC-8K-2026-09-23]
2027-06-30catalystSilverSeal hospital-channel commercializationHigh impact
Management said it recalled SilverSeal inventory from Amazon to support a hospital-market launch beginning in August and identified existing reimbursement A-codes. Sustained hospital sales and the anticipated margin benefit remain unproven. [#SEC-8K-2026-08-17]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology